Abstract
In models of acute ischaemia, erythropoietin (EPO) administration has been found to attenuate vascular injury largely through reduced apoptosis, suppressed inflammation and increased nitric oxide availability. We studied the association between circulating endogenous EPO and no-reflow in patients with first ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).
Lingua originale | English |
---|---|
pagine (da-a) | 1210-1219 |
Numero di pagine | 10 |
Rivista | European Journal of Clinical Investigation |
Volume | 41 |
DOI | |
Stato di pubblicazione | Pubblicato - 2011 |
Keywords
- Aged
- Biological Markers
- Coronary Angiography
- Electrocardiography
- Erythropoietin
- Female
- Humans
- Male
- Middle Aged
- Myocardial Infarction
- No-Reflow Phenomenon
- Regression Analysis